SCHEMBL20239207

SCHEMBL20239207

NCc1cc(Oc2ccc(CS(N)(=O)=O)cc2)nc(N)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 1/20 0.46
NPC1 O15118 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
DGAT2 Q96PD7 1/20 0.43
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA5A P35218 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NUDT1 P36639 1/20 0.35
ST14 Q9Y5Y6 1/20 0.35
LOXL2 Q9Y4K0 4/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738665 0.86 DGAT2 (0.44) SMN1; SMN2RAB9AALDH1A1NPC1MEN1
SCHEMBL20252446 0.83 DGAT2 (0.42) SMN1; SMN2RAB9AALDH1A1NPC1MEN1
SCHEMBL20239260 0.83 DGAT2 (0.46) SMN1; SMN2RAB9AALDH1A1NPC1MEN1
SCHEMBL20239235 0.82 DGAT2 (0.44) SMN1; SMN2RAB9AALDH1A1NPC1MEN1
SCHEMBL20239209 0.79 PGR (0.49) SMN1; SMN2RAB9AALDH1A1NPC1MEN1
SCHEMBL20239204 0.79 DGAT2 (0.69) SMN1; SMN2RAB9AALDH1A1NPC1MEN1
SCHEMBL20239337 0.78 DGAT2 (0.58) SMN1; SMN2RAB9AALDH1A1NPC1MEN1
SCHEMBL20239273 0.77 DGAT2 (0.70) SMN1; SMN2ALDH1A1MEN1KMT2ADGAT2
SCHEMBL20239178 0.77 DGAT2 (0.55) SMN1; SMN2ALDH1A1MEN1KMT2ADGAT2
SCHEMBL20259075 0.77 DGAT2 (0.43) SMN1; SMN2RAB9AALDH1A1NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT SMN1; SMN2 4828/4885RAB9A 1170/4885ALDH1A1 1430/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT SMN1; SMN2 4835/4885RAB9A 1119/4885ALDH1A1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.